New drugs bill to regulate imports, manufacturing of medicines to be considered by Indian lawmakers

Published On 2023-07-15 09:00 GMT | Update On 2023-07-15 09:00 GMT

New Delhi: India's lawmakers will consider a new drugs bill next week on rules for importing, manufacturing and selling medicines, according to a parliamentary notice on Thursday, as the country seeks to draw lessons from a deadly cough syrup scandal.

India's "pharmacy of the world" image has suffered some damage after cough syrups made there were linked to the death of at least 89 children in Gambia and Uzbekistan last year.

The bill is aimed at ensuring "quality, safety, efficacy, performance and clinical trial of new drugs ... with the objective of highest possible regulatory standards and a transparent regulatory regime," the notice said.

It was not immediately clear what the changes were in the new Drugs, Medical Devices and Cosmetics Bill, 2023, which will replace an earlier drugs law if passed by the parliament when it reconvenes after a break on July 20.

India's $41 billion pharmaceutical industry is one the largest in the world and has for years helped provide cheaper alternatives to Western products, especially to poor and developing nations.

But the recent cough syrup-related deaths and at least one other instance of an India-made eye drop being linked to three deaths in the United States, has cast a shadow on the industry's image.

India has made tests mandatory for cough syrup exports since last month. Companies that manufactured the syrups linked to deaths in Gambia and Uzbekistan have denied any wrongdoing

Read also: Centre should regulate manufacturing of drugs instead of state bodies, new bill moots

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

New drugs bill to regulate imports, manufacturing of medicines to be considered by Indian lawmakers

Similar News

Chennai Court Acquits 2 After Alleged Nitravet Haul Found to Be Paracetamol

USFDA warns pharma cos to remove misleading ads

Intas Pharma appoints Dr Ajay Kumar Handa as new Executive Vice President - RnD

Sun Pharma Halol facility gets OAI status from USFDA

Sanofi gets USFDA fast track designation for neovascular age-related macular degeneration gene therapy

Braille Labels, QR Code Voice Assistance on Drugs? CDSCO Seeks Stakeholder Comments

Tata Elxsi inaugrates Bayer Development Centre in Radiology at Pune

NPPA Notifies Ceiling Prices for IV Fluids in Advanced Packaging Formats, Details